Despite the presence of programmed death-ligand 1 (PD-L1) in >50% HNSCC patients, only a minority of patients with HNSCC (< 20%) respond to ICI immunotherapy.17,36 From the perspective of tumour, the HNSCCs may have adopted different types of immune-escape strategies. The gene discussed is CD274; the disease is neoplasm.